Asian Pac J Allergy Immunol:自备的高渗盐水鼻腔冲洗对过敏性鼻炎的效果研究

2018-12-25 AlexYang MedSci原创

鼻腔高渗盐水冲洗已经被报道是过敏性鼻炎(AR)辅助治疗的有效方法,但是关于副作用事件、供给为问题以及高昂的花费的考虑限制了其广泛的临床使用。由患者自备的用饮用水制成的1.8%氯化钠生理盐水溶液鼻腔冲洗(SPHNSI)能够解决部分的问题,但是它的临床效果和安全性还需要进一步调查。最近,有研究人员比较了1.8%SPHNSI和0.9%的商业等渗鼻盐水冲洗(0.9%CINSI)在AR患者中治疗的效果和安全

鼻腔高渗盐水冲洗已经被报道是过敏性鼻炎(AR)辅助治疗的有效方法,但是关于副作用事件、供给问题以及高昂的花费的考虑限制了其广泛的临床使用。由患者自备的用饮用水制成的1.8%氯化钠生理盐水溶液鼻腔冲洗(SPHNSI)能够解决部分的问题,但是它的临床效果和安全性还需要进一步调查。

最近,有研究人员比较了1.8%SPHNSI和0.9%的商业等渗鼻盐水冲洗(0.9%CINSI)在AR患者中治疗的效果和安全性。研究是一个随机、单盲和安慰剂-对照试验研究,总共包括了78名患有AR的患者。每名患者均随机的接受80ml 1.8%SPHNSI或者0.9%CINSI,每天2次,一共4周。研究发现,在第4周,与那些进行0.9%CINSI患者相比,1.8%SPHNSI鼻腔灌洗患者的Rcq-36得分显著提高(54% vs 50%;p<0.032),另外,充血症状评分也得到了显著的改善(96% vs 84%; p < 0.018)。更多的是,2个小组在第4周时发生的副作用事件相当。

最后,研究人员指出,他们的研究表明了AR患者中1.8%SPHNSI为期4周常规使用是安全的,并且比商业化的0.9%CINSI在减轻充血和提高生活质量评分上效果更好。

原始出处:

Sansila K, Eiamprapai P, Sawangjit R et al. Effects of self-prepared hypertonic nasal saline irrigation in allergic rhinitis: A randomized controlled trial. Asian Pac J Allergy Immunol. 09 Dec 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1956451, encodeId=7425195645133, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 06:32:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739940, encodeId=136d1e39940d4, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Sat May 04 22:32:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924683, encodeId=bf7e19246835e, content=<a href='/topic/show?id=35161024e48e' target=_blank style='color:#2F92EE;'>#高渗盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102474, encryptionId=35161024e48e, topicName=高渗盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Mar 02 01:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047055, encodeId=ac6f204e055f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 20 18:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780098, encodeId=bb921e8009879, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 12 10:32:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329187, encodeId=d6ac132918eca, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465844, encodeId=a0a714658445d, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046705, encodeId=e8721046e050b, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Dec 25 18:32:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
    2019-02-28 医者仁心
  2. [GetPortalCommentsPageByObjectIdResponse(id=1956451, encodeId=7425195645133, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 06:32:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739940, encodeId=136d1e39940d4, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Sat May 04 22:32:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924683, encodeId=bf7e19246835e, content=<a href='/topic/show?id=35161024e48e' target=_blank style='color:#2F92EE;'>#高渗盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102474, encryptionId=35161024e48e, topicName=高渗盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Mar 02 01:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047055, encodeId=ac6f204e055f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 20 18:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780098, encodeId=bb921e8009879, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 12 10:32:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329187, encodeId=d6ac132918eca, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465844, encodeId=a0a714658445d, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046705, encodeId=e8721046e050b, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Dec 25 18:32:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1956451, encodeId=7425195645133, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 06:32:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739940, encodeId=136d1e39940d4, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Sat May 04 22:32:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924683, encodeId=bf7e19246835e, content=<a href='/topic/show?id=35161024e48e' target=_blank style='color:#2F92EE;'>#高渗盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102474, encryptionId=35161024e48e, topicName=高渗盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Mar 02 01:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047055, encodeId=ac6f204e055f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 20 18:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780098, encodeId=bb921e8009879, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 12 10:32:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329187, encodeId=d6ac132918eca, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465844, encodeId=a0a714658445d, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046705, encodeId=e8721046e050b, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Dec 25 18:32:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1956451, encodeId=7425195645133, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 06:32:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739940, encodeId=136d1e39940d4, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Sat May 04 22:32:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924683, encodeId=bf7e19246835e, content=<a href='/topic/show?id=35161024e48e' target=_blank style='color:#2F92EE;'>#高渗盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102474, encryptionId=35161024e48e, topicName=高渗盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Mar 02 01:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047055, encodeId=ac6f204e055f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 20 18:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780098, encodeId=bb921e8009879, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 12 10:32:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329187, encodeId=d6ac132918eca, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465844, encodeId=a0a714658445d, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046705, encodeId=e8721046e050b, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Dec 25 18:32:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1956451, encodeId=7425195645133, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 06:32:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739940, encodeId=136d1e39940d4, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Sat May 04 22:32:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924683, encodeId=bf7e19246835e, content=<a href='/topic/show?id=35161024e48e' target=_blank style='color:#2F92EE;'>#高渗盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102474, encryptionId=35161024e48e, topicName=高渗盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Mar 02 01:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047055, encodeId=ac6f204e055f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 20 18:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780098, encodeId=bb921e8009879, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 12 10:32:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329187, encodeId=d6ac132918eca, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465844, encodeId=a0a714658445d, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046705, encodeId=e8721046e050b, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Dec 25 18:32:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
    2019-06-12 luwei00
  6. [GetPortalCommentsPageByObjectIdResponse(id=1956451, encodeId=7425195645133, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 06:32:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739940, encodeId=136d1e39940d4, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Sat May 04 22:32:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924683, encodeId=bf7e19246835e, content=<a href='/topic/show?id=35161024e48e' target=_blank style='color:#2F92EE;'>#高渗盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102474, encryptionId=35161024e48e, topicName=高渗盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Mar 02 01:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047055, encodeId=ac6f204e055f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 20 18:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780098, encodeId=bb921e8009879, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 12 10:32:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329187, encodeId=d6ac132918eca, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465844, encodeId=a0a714658445d, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046705, encodeId=e8721046e050b, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Dec 25 18:32:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
    2018-12-27 膀胱癌
  7. [GetPortalCommentsPageByObjectIdResponse(id=1956451, encodeId=7425195645133, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 06:32:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739940, encodeId=136d1e39940d4, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Sat May 04 22:32:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924683, encodeId=bf7e19246835e, content=<a href='/topic/show?id=35161024e48e' target=_blank style='color:#2F92EE;'>#高渗盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102474, encryptionId=35161024e48e, topicName=高渗盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Mar 02 01:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047055, encodeId=ac6f204e055f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 20 18:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780098, encodeId=bb921e8009879, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 12 10:32:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329187, encodeId=d6ac132918eca, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465844, encodeId=a0a714658445d, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046705, encodeId=e8721046e050b, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Dec 25 18:32:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
    2018-12-27 mnda
  8. [GetPortalCommentsPageByObjectIdResponse(id=1956451, encodeId=7425195645133, content=<a href='/topic/show?id=b9292862f3' target=_blank style='color:#2F92EE;'>#Asian#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2862, encryptionId=b9292862f3, topicName=Asian)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 28 06:32:00 CST 2019, time=2019-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739940, encodeId=136d1e39940d4, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Sat May 04 22:32:00 CST 2019, time=2019-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924683, encodeId=bf7e19246835e, content=<a href='/topic/show?id=35161024e48e' target=_blank style='color:#2F92EE;'>#高渗盐水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102474, encryptionId=35161024e48e, topicName=高渗盐水)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f76619, createdName=gj0731, createdTime=Sat Mar 02 01:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047055, encodeId=ac6f204e055f0, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Nov 20 18:32:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780098, encodeId=bb921e8009879, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Jun 12 10:32:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329187, encodeId=d6ac132918eca, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465844, encodeId=a0a714658445d, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Thu Dec 27 06:32:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046705, encodeId=e8721046e050b, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Dec 25 18:32:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
    2018-12-25 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

Environ Int:中国儿童喘息和鼻炎的发病和缓解研究

在中国,很少有纵向研究关于儿童室内和室外空气污染接触和相关呼吸道疾病。最近,有研究人员在中国儿童中研究了室内和室外环境与喘息和鼻炎之间的相关性。研究包括了3-6岁的儿童,并随机来自于6个城市。研究人员通过一个父母调查问卷来对喘息、鼻炎和家庭环境数据进行评估,并利用出生后前2年和跟踪调查的最后1年的流行度来计算发病和缓解情况。研究人员发现,产前NO2与喘息缓解的减少和鼻炎流行度的增加和发病的增加相关

Clin Exp Dermatol:在患有过敏性皮肤炎的中国患者中,芳香烃受体多样性与皮肤干燥相关

表皮屏障功能障碍是过敏性皮肤炎(AD)发展的一个起始事件。最近的研究鉴定了芳香烃受体(AHR)在控制丝聚合蛋白基因表达和其他皮肤屏障蛋白中的关键角色,表明了AHR与AD发病机理之间潜在的相关性。最近,有研究人员调查了AHR基因多样性在AD敏感性和AD相关表型中的作用。研究包括了487名患有AD的患者,210名患有牛皮癣的患者和226名健康对照。研究发现,AHR rs10249788和rs20668

盘点:鼻炎相关机制研究

【1】Cell Mol Biol (Noisy-le-grand):中国过敏性鼻炎儿童IL-31, IL-33和ST2血清水平调查https://www.ncbi.nlm.nih.gov/pubmed/30301503最近,有研究人员比较了儿童过敏性鼻炎(AR)和过敏性哮喘患者中IL-31, IL-33和ST2血清水平,并尝试阐释AR的发病机制。研究包括了36名患有间歇性AR的儿童患者,调查的

Molecules:黄连碱能够抑制肥大细胞的脱粒和卵清蛋白诱导的过敏性鼻炎

黄连碱是黄连异喹啉生物碱中的一种主要的组分。黄连碱对过敏性鼻炎的作用还没有调查。最近,有研究人员在小鼠模型中报道了黄连碱的作用的相关机制。研究发现,黄连碱能够显著的减少β-氨基己糖苷酶、组氨、白介素-4(IL-4)和肿瘤坏死因子α(TNF-α)的水平。黄连碱也能够预防形态学的变化,比如恢复长条形,抑制甲苯胺蓝染色颗粒的释放、重组抑制丝状肌动蛋白(F-actin)等。另外,黄连碱能够阻断磷酸肌醇3-

盘点:鼻炎与治疗进展盘点

【1】Immun Inflamm Dis:永久过敏性鼻炎患者中,MP-AzeFlu治疗效果分析https://www.ncbi.nlm.nih.gov/pubmed/30306729大多数过敏性鼻炎(AR)患者患有中度到重度以及永久性症状。MP-AzeFlu组合鼻内盐酸氮卓斯汀(AZE)和氟替卡松丙酸酯(FP)可以作为一种新的治疗方法来治疗AR。最近,有研究人员在一个前瞻性的和非介入性研究中探

盘点:近期鼻炎研究进展盘点

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与大家一起分享学习!【1】Allergy:青少年到成年人群体中,过敏性鼻炎预测因子分析虽然儿童的遗传性过敏疾病已经了解很多,但是从儿童到成年人中,遗传过敏性疾病的持久性相关知识却非常有限。最近,有研